Vertex Pharmaceuticals Incorporated
VRTX
$472.41
-$5.48-1.15%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 9.99% | 4.84% | 59.82% | -29.21% | -12.67% |
| Total Depreciation and Amortization | -54.63% | 4.45% | 6.82% | 127.23% | -59.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 541.24% | -137.30% | -69.21% | 111.93% | 62.97% |
| Change in Net Operating Assets | -733.56% | 212.99% | 50.69% | 52.07% | -455.68% |
| Cash from Operations | -59.88% | 15.68% | 31.04% | 40.08% | -57.32% |
| Capital Expenditure | -46.76% | 30.13% | -257.99% | 56.05% | -36.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -812.50% | 95.51% | -2,143.71% | 97.93% | -160.19% |
| Cash from Investing | -146.24% | 75.85% | -768.28% | 93.21% | -136.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -7.69% | 0.00% | 0.00% | 75.93% |
| Issuance of Common Stock | 583.54% | -83.91% | 194.01% | -51.31% | 308.33% |
| Repurchase of Common Stock | 88.74% | -192.21% | 42.91% | -63.83% | -8.64% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 57.14% | -12.50% | -11.11% | 0.00% |
| Cash from Financing | 93.31% | -230.61% | 48.68% | -73.88% | -0.98% |
| Foreign Exchange rate Adjustments | 278.05% | -107.17% | 87.54% | 164.48% | -307.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 509.36% | -111.53% | 162.01% | 116.75% | -202.86% |